Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 12/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 11/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11939974 | 1.00 | CDK9 (0.38) | CDK9CCNT1ESR1ESR2MEN1 | |
| SCHEMBL11938476 | 0.93 | CDK9 (0.42) | CDK9CCNT1 | |
| SCHEMBL15381715 | 0.93 | CDK9 (0.42) | CDK9CCNT1 | |
| SCHEMBL11939853 | 0.90 | CCNT1 (0.33) | CDK9CCNT1ESR1ESR2 | |
| SCHEMBL11939186 | 0.88 | CDK9 (0.36) | CDK9CCNT1ESR1ESR2MEN1 | |
| SCHEMBL11939182 | 0.88 | CCNT1 (0.36) | CDK9CCNT1ESR1ESR2 | |
| SCHEMBL12223928 | 0.88 | L3MBTL1 (0.33) | CDK9CCNT1ESR1ESR2MEN1 | |
| SCHEMBL11939272 | 0.87 | CCNT1 (0.35) | CDK9CCNT1ESR1ESR2 | |
| SCHEMBL15381543 | 0.86 | CDK9 (0.39) | CDK9CCNT1 | |
| SCHEMBL11939248 | 0.86 | CCNT1 (0.36) | CDK9CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120168677-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120168677-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CXCR1, OCIAD1, LEO1 | CDK9 575/4885CCNT1 16/4885ESR1 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.